Skip to main content

Animations

MJFF Publications

2221 - 2230 of 6422 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: Smoking is associated with age at disease onset in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.03.005
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Polygenic burden of Parkinson's disease risk stratifies the prognosis of isolated rapid-eye-movement disorder: A preliminary observational study
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.02.005
    Citation Count: 2
  • Summary Details
    OPEN
    Title: Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.022
    Citation Count: 20
  • Summary Details
    OPEN
    Title: Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.01.017
    Citation Count: 26
  • Summary Details
    OPEN
    Title: Anxiety in Parkinson's disease: A resting-state high density EEG study
    Journal Name: Neurophysiologie Clinique
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neucli.2022.01.001
    Citation Count: 17
  • Summary Details
    OPEN
    Title: Preserved motor memory in Parkinson's disease
    Journal Name: Neuropsychologia
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108161
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Special Issue on new therapeutic approaches to Parkinson disease
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998
    Citation Count: 5
  • Summary Details
    OPEN
    Title: A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105612
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109213
    Citation Count: 9
  • Summary Details
    OPEN
    Title: Body-first Parkinson’s disease and variant Creutzfeldt–Jakob disease – similar or different?
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105625
    Citation Count: 7
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.